From GLP-1 support to sustainable A new era in obesity and diabetes care.
Obesity and type 2 diabetes are global metabolic pandemics.
GLP-1 drugs, though promising, need structured support to deliver lasting impact.
Boli is an AI-powered digital therapeutic that helps GLP-1 users improve adherence, manage side effects and build sustainable lifestyle change.
Our platform delivers clinical-grade support and captures structured real-world data – fueling research, regulation, and the next generation of metabolic treatments.
Built by pioneers in digital care, Boli launches in Q1 2026.
From GLP-1 support to sustainable metabolic health. A new era in obesity and diabetes care.
Obesity and type 2 diabetes are global metabolic pandemics.
GLP-1 drugs, though promising, need structured support to deliver lasting impact.
Boli is an AI-powered digital therapeutic that helps GLP-1 users improve adherence, manage side effects and build sustainable lifestyle change.
Our platform delivers clinical-grade support and captures structured real-world data — fueling research, regulation, and the next generation of metabolic treatments.
Built by pioneers in digital care, Boli launches in Q1 2026.